With a lack of predictive models, the ability to conduct a preoperative estimation of the probability that a patient with kidney cancer will complete partial nephrectomy (PN) versus radical nephrectomy (RN) is deficient. A study from Francesco Cei, MD, MHSc, and colleagues published in Urologic Oncology sought to create an evidence-based predictive model to evaluate the probability of PN completion in accordance with patient characteristics, tumor complexity, urologist expertise, and surgical approach. ...
Renal Cell Carcinoma
Advertisement
Latest News
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Approximately 82,000 new cases of RCC are diagnosed each year in the US, but effective early detection methods are lacking.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Advertisement
Advertisement
Latest News
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
